Infographics
-
CDMO Preference For Small Molecule Drug Substance
4/13/2022
ISR asked API outsourcers which CDMOs they are currently working with and which CDMO they prefer to use for all small molecule drug substance manufacturing. Delve into the data which showed that Cambrex, Patheon, Lonza, STA Pharma and Pfizer CentreOne are the preferred CDMOs among roughly one-third of their current customers.
-
Preference Among Users: New And Emerging Biopharma
4/13/2022
ISR asked new and emerging biopharma respondents which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer.
-
Use Of Preferred Providers Among Small Molecule Outsourcers
3/16/2022
In Q32021, ISR surveyed outsourcers of small molecule API and outsourcers of small molecule drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show use of preferred providers is slightly more common for small molecule API than small molecule drug product manufacturing (56% vs. 51%).
-
Biologic Drug Product Outsourcing Drivers By Company Size
2/14/2022
The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%).
-
Small Molecule Drug Substance Outsourcing Drivers by Company Size
2/14/2022
In Q3 2021, ISR surveyed 124 sponsors who outsource small molecule drug substance manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (66%) while sponsors from non-large pharma use CMOs for all manufacturing needs (58%).
-
Small Molecule Drug Substance Pandemic Complications
1/14/2022
Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020.
-
Small Molecule Sterile Injectable Outsourcing Volume
11/15/2021
In Q2 2021, ISR asked 57 respondents how many small molecule sterile injectable products they have on the market, the proportion of sterile injectable manufacturing that is outsourced and the number of CDMOs they use to complete the work. On average, respondents have 3.4 marketed biologic products, of which 67% of drug product manufacturing is outsourced and use an average of 3.3 CDMOs. To learn how these proportions are predicted to change in the next five years, follow the link to the Sterile Injectable Market Outlook report preview.
-
Biologic Sterile Injectable Outsourcing Volume
11/15/2021
On average, respondents have 4.5 marketed biologic products, of which 65% of drug product manufacturing is outsourced. Respondents use an average of 3.3 CDMOs.
-
Manufacturing Costs For Small Molecule Development Work
10/18/2021
In Q3 2020, ISR asked 49 respondents to allocate the costs of development work and clinical trial materials for outsourced small molecule drugs. The data show that API Manufacturing and Drug Product Manufacturing and Process Development capture similar proportions of outsourced spend at this stage.
-
Top 5 Oral Dosage Forms By Expenditure
9/18/2021
In Q2 2021, ISR asked 100 outsourcers of oral dose manufacturing to allocate the proportion of their company’s outsourced expenditure by dosage form. The data show that traditional tablets currently account for the largest proportion of spend, followed by controlled release tablets and immediate release tablets. However, respondents predict some of the current spend on tablets will shift to capsules five years from now. To learn more, follow the link to the Oral Dosage Forms Market Outlook report preview.